| dc.creator | MPOB International Palm Oil Congress - PIPOC
September 25 - 29, 2005 :
Sunway Pyramid Convention Centre, Petaling Jaya, Selangor, Malaysia.
40833 | |
| dc.creator | Harlina Halizah Siraj.
54816 | |
| dc.creator | Huzwah Kaza'ai.
54817 | |
| dc.creator | Marianah Abdul Wahab.
54818 | |
| dc.creator | Mohd Sokhini Abdul Mutalib.
54819 | |
| dc.creator | Muhammad Hatta Azwar.
54820 | |
| dc.creator | Noor Azliza Wani Abd. Aziz.
54821 | |
| dc.creator | Zaleha Abdullah Mahdy.
54822 | |
| dc.date | 2005. | |
| dc.description | Preeclampsia (PE) is a multisystem disorder that remains as a major cause of maternal and foetal morbidity and mortilíty. To date, no treatment has been found that prevents the development of the disease. Endothelial dysfunction is considered to underlie its clinical manifestations, such as maternal hypertension, proteinuria and edoema; however, the precise biochemical pathways involved remain unclear. Antioxidant therapy of PE on the paradigm that overproduction of lipid peroxides contribute to the endothelial cell activation has been suggested. In the present study, the potential of palm tocotrienols in the prevention of pregnancy induced hypertension (PIH) and PE has been investigated. A randomized doubleblind placebo-controlled clinical trial, palm tocotrienols 100mg daily or placebo was prescribed on healthy normotensive non-proteinuric primigravidae from early second trimester, before 16 weeks gestation, until delivery. The primary outcome measure was the incidence of PIH and PE. Out of the 299 women recruited, 151 were randomized into palm tocotrienols arm and 148 into the placebo arm. A total of 15 (5.0 percent) developed PIH and 6 (2.0 percent) develop PE. Although there was no statistically significant difference in the incidence of PIH (4/151 or 2.6 percent in the palm tocotrienols arm vs 11/148 or 7.4 percent in the placebo arm, p0.058) or PE (1/151 or 0.7 percent in the TRF arm vs 5/148 or 3.4 percent in the placebo arm, p0.094) between the two arms, there was a tendency towards lower incidences of both PIH and PE in the palm tocotrienols arm compared to the placebo arm. With palm tocotrienols supplementation, the relative risk (RR) of PIH was 0.36 (95 percent CI 0.12-1.09) and of PE was 0.20 (95 percent CI 0.02-1.66). This first clinical trial using palm tocotrienols is shown to have potential protective effect against PIH and PE. This is in contrast with recent reports of the ineffectiveness of other antioxidants such as combined tocopherol and vitamin C as prophylaxis measures. The current findings warrant larger clinical trials in both low risk as well as high risk populations. | |
| dc.description | Preeclampsia (PE) is a multisystem disorder that remains as a major cause of maternal and foetal morbidity and mortilíty. To date, no treatment has been found that prevents the development of the disease. Endothelial dysfunction is considered to underlie its clinical manifestations, such as maternal hypertension, proteinuria and edoema; however, the precise biochemical pathways involved remain unclear. Antioxidant therapy of PE on the paradigm that overproduction of lipid peroxides contribute to the endothelial cell activation has been suggested. In the present study, the potential of palm tocotrienols in the prevention of pregnancy induced hypertension (PIH) and PE has been investigated. A randomized doubleblind placebo-controlled clinical trial, palm tocotrienols 100mg daily or placebo was prescribed on healthy normotensive non-proteinuric primigravidae from early second trimester, before 16 weeks gestation, until delivery. The primary outcome measure was the incidence of PIH and PE. Out of the 299 women recruited, 151 were randomized into palm tocotrienols arm and 148 into the placebo arm. A total of 15 (5.0 percent) developed PIH and 6 (2.0 percent) develop PE. Although there was no statistically significant difference in the incidence of PIH (4/151 or 2.6 percent in the palm tocotrienols arm vs 11/148 or 7.4 percent in the placebo arm, p0.058) or PE (1/151 or 0.7 percent in the TRF arm vs 5/148 or 3.4 percent in the placebo arm, p0.094) between the two arms, there was a tendency towards lower incidences of both PIH and PE in the palm tocotrienols arm compared to the placebo arm. With palm tocotrienols supplementation, the relative risk (RR) of PIH was 0.36 (95 percent CI 0.12-1.09) and of PE was 0.20 (95 percent CI 0.02-1.66). This first clinical trial using palm tocotrienols is shown to have potential protective effect against PIH and PE. This is in contrast with recent reports of the ineffectiveness of other antioxidants such as combined tocopherol and vitamin C as prophylaxis measures. The current findings warrant larger clinical trials in both low risk as well as high risk populations. | |
| dc.language | ng | |
| dc.publisher | Petaling Jaya : MPOB, | |
| dc.subject | Aceite de palma | |
| dc.subject | Antioxidantes. | |
| dc.subject | Salud. | |
| dc.subject | Tocotrienoles. | |
| dc.title | Palm Tocotrienols : A Potential Hope for Pre-eclampsia Patients. | |
| dc.type | text | |
